Agios director awarded 1,447 common shares via RSU vesting

AGIOS PHARMACEUTICALS, INC. director Jay T. Backstrom reported equity compensation activity.

Accepted by SEC EDGAR 07/10/2026 - 04:18 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

AGIOS PHARMACEUTICALS, INC. director Jay T. Backstrom reported equity compensation activity. On July 8, 2026, he acquired 1,447 shares of common stock at no cost, in connection with the exercise/vesting of 1,447 restricted stock units (RSUs). Following these transactions, he directly holds 1,447 common shares and 2,894 RSUs. The RSUs were originally granted on July 8, 2025 and are scheduled to vest in three equal annual installments beginning July 8, 2026.

Insider Trade Summary

1,447 shares exercised/converted

Exercise 2 txns

Insider Backstrom Jay T.

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted stock units F1, F2	1,447	$0.00	$0.00
Grant/Award	Common stock	1,447	$0.00	$0.00

Holdings After Transaction: Restricted stock units — 2,894 contracts (Direct); Common stock — 1,447 shares (Direct)

Holdings Before and After: Restricted stock units, 4,341 to 2,894 contracts (Direct); Common stock, 0 to 1,447 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
2. F2. The restricted stock units were granted on July 8, 2025. Beginning on July 8, 2026, the shares underlying the restricted stock units will vest in three equal annual installments.

Key Figures

Common shares acquired: 1,447 shares RSUs converted: 1,447 RSUs Common shares held after: 1,447 shares +3 more

6 metrics

Common shares acquired 1,447 shares Grant/award acquisition of common stock on July 8, 2026 at $0.0000 per share

RSUs converted 1,447 RSUs Exercise or conversion of restricted stock units into common stock on July 8, 2026

Common shares held after 1,447 shares Total direct common stock ownership following the reported transactions

RSUs outstanding after 2,894 RSUs Total restricted stock units remaining following the derivative transaction

Grant date of RSUs July 8, 2025 Original grant date of the restricted stock units described in the footnotes

RSU vesting start July 8, 2026 Date from which RSU shares will vest in three equal annual installments

Key Terms

restricted stock units, contingent right, derivative security, vest

4 terms

restricted stock units financial

"The restricted stock units were granted on July 8, 2025."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"Each restricted stock unit represents a contingent right to receive one share"

derivative security financial

"Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

vest financial

"the shares underlying the restricted stock units will vest in three equal annual installments"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AGIO director Jay T. Backstrom report?

Jay T. Backstrom reported acquiring 1,447 shares of AGIO common stock at no cost on July 8, 2026, through the vesting and conversion of restricted stock units.

How many AGIO common shares does Jay T. Backstrom hold after this Form 4?

After the reported transactions, Jay T. Backstrom directly holds 1,447 shares of AGIOS PHARMACEUTICALS, INC. common stock, according to the Form 4 ownership table.

How many restricted stock units does AGIO director Backstrom have remaining?

Following the July 8, 2026 transactions, Jay T. Backstrom has 2,894 restricted stock units (RSUs) outstanding, representing a contingent right to receive the same number of AGIO common shares.

When were Jay T. Backstrom’s AGIO restricted stock units granted and how do they vest?

The restricted stock units were granted on July 8, 2025 and, beginning July 8, 2026, the shares underlying the RSUs will vest in three equal annual installments.

Did Jay T. Backstrom buy or sell AGIO shares on the open market?

No open-market trades were reported. The Form 4 shows a grant/award acquisition of 1,447 common shares and an exercise/conversion of 1,447 RSUs, both at a price of $0.0000 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Backstrom Jay T.

(Last) (First) (Middle)

C/O AGIOS PHARMACEUTICALS, INC.

88 SIDNEY STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AGIOS PHARMACEUTICALS, INC. [ AGIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	07/08/2026		A		1,447	A	$0	1,447	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted stock units	(1)	07/08/2026		M			1,447	(2)	(2)	Common stock	1,447	$0	2,894	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

2. The restricted stock units were granted on July 8, 2025. Beginning on July 8, 2026, the shares underlying the restricted stock units will vest in three equal annual installments.

Remarks:

	/s/ William Cook, as attorney-in-fact for Jay Backstrom	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)